Physician profile
Emily Sara Blum
NPI 1912137431
$18,711.80
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Pediatric Urology providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.31 · 2020: $249 · 2021: $150 · 2022: $1,222 · 2023: $699 · 2024: $1,002 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $3,383 · Food and Beverage: $2,558 · Travel and Lodging: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,021.50 |
| Consulting Fee | $3,382.50 |
| Food and Beverage | $2,557.51 |
| Travel and Lodging | $1,127.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $11,781.81 | 2023-2025 | Rivfloza |
| C. R. Bard, INC. & Subsidiaries | $3,520.23 | 2023-2025 | Magic3 Go Intermittent Urinary Catheter |
| Boston Scientific Corporation | $1,202.62 | 2021-2025 | Lithovue, Spaceoar System, General - Therapies |
| Palette Life Sciences, INC. | $880.50 | 2020-2022 | |
| Teleflex LLC | $626.54 | 2024-2025 | Deflux, Deflux Metal Needle |
| Lazarus 3d | $200.00 | 2022 | |
| Novo Nordisk Health Care Ag | $124.28 | 2024 | |
| Blue Earth Diagnostics | $121.34 | 2021-2023 | |
| Axonics, INC. | $69.79 | 2022 | |
| Bracco Diagnostics INC. | $43.24 | 2025 | |
| Merck Sharp & Dohme LLC | $33.74 | 2024 | Keytruda |
| Dendreon Pharmaceuticals LLC | $33.50 | 2024 | Provenge |
| Innovation Technologies INC | $25.36 | 2025 | Irrisept |
| Myriad Genetic Laboratories, INC. | $23.22 | 2025 | Prolaris |
| Myovant Sciences INC. | $20.50 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $5.13 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.